Cabezas C, Echevarría C, Gómez G, Gotuzzo E
Instituto de Medicina Tropical Alexander von Humboldt Universidad Peruana Cayetano Heredia, Lima-Perú.
Rev Gastroenterol Peru. 1995 Sep-Dec;15(3):215-22.
Abancay is located at 2,395 m.a.s.l. in the Peruvian Andean Region. It is a hyperendemic area for Hepatitis B virus (HBV) and hepatitis delta virus (HDV) infection, where 7% of the deaths are caused by acute and chronic hepatitis infections. In 1991, a pilot immunization program against HBV infection was started to control the incidence of VHB-VHD, and as a strategy to improve the EPI coverage in general.
Vaccination population was programmed to include 1,301 children under 1 year old and 3,488 children between 1-4 years old. A total of 3 doses of DNA recombinant vaccine against HBV per child were administered. The vaccination schedule fit within the EPI immunization schedule. For children under one year old, the program includes: Newborn: BCG, Polio 1, HBV1; 2-month old: Polio 2, DPT1, HBV2; 3-month old: DPT2, Polio 3; 4-month old: polio 4, HBV 3 and; 9 month old: Measles. For children aged between 1 and 4 years old, the program includes: HBV1, HBV2 one month after HBV1, and HBV six months after HBV1.
One year after the immunization program started, 1,262 (97.0%) children under one year old and 2,529 (72.5%) between 1-4 years old were immunized. No relevant adverse effects have been reported. There were 8 deaths due to acute respiratory infection and acute diarrhea diseases, which are the main causes of death in this area. One of the objectives achieved was an improvement in the EPI vaccination coverage for children younger than 1 year old, with a DPT coverage of 97.0% in 1991 compared to 63.0% in 1988, 26.9% in 1989, and 61.9% in 1990.
The inclusion of HVB vaccination in the EPI for a HBV and HDV endemic area improves the total EPI coverage and it is safe an effective.
阿班凯位于秘鲁安第斯地区,海拔2395米。它是乙肝病毒(HBV)和丁型肝炎病毒(HDV)感染的高度流行区,7%的死亡由急慢性肝炎感染所致。1991年,启动了一项针对HBV感染的试点免疫计划,以控制VHB - VHD的发病率,并作为总体上提高扩大免疫规划(EPI)覆盖率的一项策略。
计划接种人群包括1301名1岁以下儿童和3488名1 - 4岁儿童。每名儿童共接种3剂重组DNA乙肝疫苗。接种时间表符合EPI免疫接种时间表。对于1岁以下儿童,该计划包括:新生儿:卡介苗、脊髓灰质炎疫苗1、乙肝疫苗1;2个月大:脊髓灰质炎疫苗2、百白破疫苗1、乙肝疫苗2;3个月大:百白破疫苗2、脊髓灰质炎疫苗3;4个月大:脊髓灰质炎疫苗4、乙肝疫苗3;9个月大:麻疹疫苗。对于1 - 4岁儿童,该计划包括:乙肝疫苗1、在接种乙肝疫苗1后1个月接种乙肝疫苗2,在接种乙肝疫苗1后6个月接种乙肝疫苗3。
免疫计划启动一年后,1262名(97.0%)1岁以下儿童和2529名(72.5%)1 - 4岁儿童完成了免疫接种。未报告相关不良反应。有8例因急性呼吸道感染和急性腹泻疾病死亡,这是该地区的主要死因。实现的目标之一是1岁以下儿童的EPI疫苗接种覆盖率有所提高,1991年百白破疫苗覆盖率为97.0%,而1988年为63.0%,1989年为26.9%,1990年为61.9%。
在HBV和HDV流行地区将乙肝疫苗接种纳入EPI可提高EPI的总体覆盖率,且安全有效。